ES2110764T3 - Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6. - Google Patents

Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6.

Info

Publication number
ES2110764T3
ES2110764T3 ES94918396T ES94918396T ES2110764T3 ES 2110764 T3 ES2110764 T3 ES 2110764T3 ES 94918396 T ES94918396 T ES 94918396T ES 94918396 T ES94918396 T ES 94918396T ES 2110764 T3 ES2110764 T3 ES 2110764T3
Authority
ES
Spain
Prior art keywords
cell
epitope
cd44v6
cells
hermes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918396T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Corp
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22141703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2110764(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Application granted granted Critical
Publication of ES2110764T3 publication Critical patent/ES2110764T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UN ANTICUERPO MONOCLONAL (DSM ACC 123) QUE SE FIJA SOLO A FORMAS DE CD44 QUE CONTIENE LA SECUENCIA DE AMINOACIDO QUE CODIFICA EXON V6, PERO NO LA FORMA ESTANDARD DE 90 KILODALTONS DE CD44 DE LINFOCITO Y AL USO DE TALES ANTICUERPOS PARA DETECTAR LA PRESENCIA DE CD44V6 EN TEJIDOS O CELULAS PARA DETERMINAR SI EL TEJIDO EPITELIAL DE UN ANIMAL O HUMANO HA SUFRIDO UNA TRANSFORMACION MALIGNA, PARA DETERMINAR EL POTENCIAL METASTATICO DE LAS CELULAS MALIGNAS Y PARA DETECTAR ENFERMEDADES INFLAMATORIAS EN LOS PACIENTES.
ES94918396T 1993-06-18 1994-06-16 Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6. Expired - Lifetime ES2110764T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7806393A 1993-06-18 1993-06-18

Publications (1)

Publication Number Publication Date
ES2110764T3 true ES2110764T3 (es) 1998-02-16

Family

ID=22141703

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918396T Expired - Lifetime ES2110764T3 (es) 1993-06-18 1994-06-16 Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6.

Country Status (13)

Country Link
US (1) US5616468A (es)
EP (1) EP0703989B1 (es)
JP (1) JPH08511419A (es)
AT (1) ATE159953T1 (es)
AU (1) AU678487B2 (es)
CA (1) CA2165461A1 (es)
DE (1) DE69406664T2 (es)
DK (1) DK0703989T3 (es)
ES (1) ES2110764T3 (es)
GR (1) GR3025759T3 (es)
IL (1) IL110070A0 (es)
WO (1) WO1995000658A1 (es)
ZA (1) ZA944383B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134982A1 (de) * 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression
JP3431922B2 (ja) * 1992-06-09 2003-07-28 オイ バイオティエ セラピーズ リミテッド 炎症性疾患および自己免疫疾患の診断用組成物および診断方法
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19545472A1 (de) * 1995-12-06 1997-06-12 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
ES2533002T3 (es) * 2004-03-10 2015-04-06 Creighton University Receptores estrogénicos y métodos de uso
US20050214880A1 (en) * 2004-03-26 2005-09-29 University Of Miami Salivary soluble CD44: a molecular marker for head and neck cancer
EP2041299A4 (en) * 2006-07-14 2010-01-13 Aviva Biosciences Corp METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE
US20080057505A1 (en) * 2006-07-14 2008-03-06 Ping Lin Methods and compositions for detecting rare cells from a biological sample
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
CN103648517B (zh) * 2011-03-24 2016-04-20 纽瑞姆制药（1991）有限公司 神经保护肽
RU2017104284A (ru) 2014-07-15 2018-08-15 Йиссум Рисеч Девелопмент Компани Оф Зе Хебрю Юниверсити Оф Джерусалем Лтд. Выделенные полипептиды cd44 и их применение

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014510A1 (de) 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DE4134982A1 (de) 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression

Also Published As

Publication number Publication date
DE69406664D1 (de) 1997-12-11
ATE159953T1 (de) 1997-11-15
AU6972694A (en) 1995-01-17
DE69406664T2 (de) 1998-06-04
IL110070A0 (en) 1994-10-07
EP0703989B1 (en) 1997-11-05
DK0703989T3 (da) 1998-02-09
AU678487B2 (en) 1997-05-29
CA2165461A1 (en) 1995-01-05
GR3025759T3 (en) 1998-03-31
WO1995000658A1 (en) 1995-01-05
US5616468A (en) 1997-04-01
ZA944383B (en) 1995-03-03
JPH08511419A (ja) 1996-12-03
EP0703989A1 (en) 1996-04-03

Similar Documents

Publication Publication Date Title
ES2110764T3 (es) Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6.
Meigel et al. Dermal architecture and collagen type distribution
Bukovský et al. The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube.
Heyderman et al. A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2
Weiss et al. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function
Liu et al. KAI1/CD82, a tumor metastasis suppressor
Fogel et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma
Hormia et al. Expression of cytokeratins in odontogenic jaw cysts: monoclonal antibodies reveal distinct variation between different cyst types
De Young et al. CD31 immunoreactivity in carcinomas and mesotheliomas
Bordessoule et al. Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67
Saga Histochemical and immunohistochemical markers for human eccrine and apocrine sweat glands: an aid for histopathologic differentiation of sweat gland tumors
Cagnano et al. Expression of ligands to NKp46 in benign and malignant melanocytes
Rochaix et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen
Kunz et al. Epidermal expression of the calcium binding surface antigen 27E10 in inflammatory skin diseases
Posnett et al. A membrane antigen (HC1) selectively present on hairy cell leukemia cells, endothelial cells, and epidermal basal cells.
Tiitta et al. Tenascin in inflammatory conditions and neoplasms of the urinary bladder
Lohi et al. Expression of type IV collagen α1 (IV)–α6 (IV) polypeptides in normal and developing human kidney and in renal cell carcinomas and oncocytomas
Georgolios et al. THE ROLE OF CD�� ADHESION MOLECULE IN ORAL CAVITY CANCER
Fujimura et al. Aminopeptidase A expression in cervical neoplasia and its relationship to neoplastic transformation and progression
Löning et al. The epithelial framework of the thymus in normal and pathological conditions: Immunohistochemical demonstration of keratin in an autopsy series
Goepel et al. Tenascin—a marker for the malignant potential of preinvasive breast cancers
Autio-Harmainen et al. Laminin and type IV collagen in different histological stages of Kaposi's sarcoma and other vascular lesions of blood vessel or lymphatic vessel origin
Schaider et al. CD44 and variants in melanocytic skin neoplasms
Mori et al. Immunohistochemical demonstration of epithelial membrane antigen (EMA), carcinoembryonic antigen (CEA), and keratin on mammary and extramammary Paget's disease
Hale et al. Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 703989

Country of ref document: ES